APA (7th ed.) Citation

Schjesvold, F., Paiva, B., Ribrag, V., Rodriguez-Otero, P., San-Miguel, J. F., Robak, P., . . . Raab, M. (2023). Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma. Clinical lymphoma, myeloma & leukemia, 23(1), . https://doi.org/10.1016/j.clml.2022.10.006

Chicago Style (17th ed.) Citation

Schjesvold, Fredrik, et al. "Cobimetinib Alone and Plus Venetoclax With/without Atezolizumab in Patients with Relapsed/refractory Multiple Myeloma." Clinical Lymphoma, Myeloma & Leukemia 23, no. 1 (2023). https://doi.org/10.1016/j.clml.2022.10.006.

MLA (9th ed.) Citation

Schjesvold, Fredrik, et al. "Cobimetinib Alone and Plus Venetoclax With/without Atezolizumab in Patients with Relapsed/refractory Multiple Myeloma." Clinical Lymphoma, Myeloma & Leukemia, vol. 23, no. 1, 2023, https://doi.org/10.1016/j.clml.2022.10.006.